Indiabulls Pharma receives Rs 155 crore investment from Clermont Group

MUMBAI: Indiabulls Pharmaceuticals, a one year old pharma venture of Indiabulls Group Companies, on Monday announced that it has received Rs 155 Cr capital from Singapore based investment firm Clermont Group.

Indiabulls Pharma said this new development will further boost an already rapidly growing business which the company has witnessed since its launch in May 2017.

The investment will bolster the company’s ambition of becoming a leading provider of healthcare products and services in India and be amongst the top 10 players in the coming decade.

“At Indiabulls Pharmaceuticals, we want to reshape the Indian pharmaceutical industry landscape by providing next generation therapies to patients at affordable prices. We aspire to be a patient and physician centric, innovative, best-in-class pharmaceutical company,” said Mr. Nikhil Chari, CEO of Indiabulls Pharmaceuticals

Chari added that the new development provides capital for growth for years to come and puts Indiabulls Pharmaceuticals on a firm path to be a leading pharmaceutical company in the coming decade.

The Indiabulls Group has businesses spanning housing finance, consumer finance, real estate, and pharmaceuticals sectors.

The company added that its business aspiration is to be a leading patient and physician centric, best in class, innovative healthcare company. It operates in both chronic and acute therapies and also across health, wellness and cosmoceutical categories. Currently the company has 300 products under its portfolio many being first time in India formulations and devices.